Pharmaceutical companies can trade sideways for years, and may see a spike every now and then due to positive announcements or an FDA approval update. The newest subset of the biotech industry, known as gene therapy companies, has been multiplying at an astonishing rate. As a result, they have many new stocks listed to capital markets. These companies have recently piqued the interest of investors, and analysts are weighing in.
Many individuals are born with disorders for which there is no cure, or for which only meager treatments exist to improve their quality of life. However, with gene therapy, it is said that entire ailments can be eliminated after just one treatment that targets their source. Faulty genes can be repaired by implanting viral genetic material into the DNA and RNA chains.
In a lengthy report on the upsides of gene therapy in the biotech industry, Yun Zhong of BTIG explained that many companies of this sort are trading near their 52-week lows, and as such are poised for a buying opportunity. He opined that the challenges and setbacks faced by these firms are naturally occurring growing pains for the industry as a whole, and will serve as net positives once investors move past them.
#therapy #update #gene #company #trade #genetherapy #pharmaceutical #industry #fda #companies #biotech #worldlynewsonline